252 related articles for article (PubMed ID: 16915539)
1. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H
Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539
[TBL] [Abstract][Full Text] [Related]
2. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
3. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
4. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
5. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
6. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
7. The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy.
Czarnywojtek A; Zgorzalewicz-Stachowiak M; Budny B; Wasko R; Florek E; Szczepanek E; Komar-Rychlicka K; Waligorska-Stachura J; Kurdybacha P; Miechowicz I; Ruchala M
Neuro Endocrinol Lett; 2013; 34(3):241-8. PubMed ID: 23685424
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis.
Shiber S; Stiebel-Kalish H; Shimon I; Grossman A; Robenshtok E
Thyroid; 2014 Oct; 24(10):1515-23. PubMed ID: 25068172
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Four Treatments in Patients with Graves' Disease: a Network Meta-analysis.
Ren Z; Qin L; Wang JQ; Li Y; Li J; Zhang RG
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):317-22. PubMed ID: 25988881
[TBL] [Abstract][Full Text] [Related]
10. Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe.
Rosetti S; Tanda ML; Veronesi G; Masiello E; Premoli P; Gallo D; Cusini C; Donati S; Sabatino J; Ippolito S; Piantanida E; Bartalena L
J Endocrinol Invest; 2020 Mar; 43(3):381-383. PubMed ID: 31587179
[No Abstract] [Full Text] [Related]
11. Radioiodine therapy and Graves' disease - Myths and reality.
Plazinska MT; Sawicka-Gutaj N; Czarnywojtek A; Wolinski K; Kobylecka M; Karlińska M; Prasek K; Zgorzalewicz-Stachowiak M; Borowska M; Gut P; Ruchala M; Krolicki L
PLoS One; 2020; 15(1):e0226495. PubMed ID: 31929534
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
[TBL] [Abstract][Full Text] [Related]
13. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
14. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
15. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
[TBL] [Abstract][Full Text] [Related]
16. Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
18. Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association.
Lazarus JH; Bartalena L; Marcocci C; Kahaly GJ; Krassas G; Wiersinga WM;
J Endocrinol Invest; 2010 Jun; 33(6):409-13. PubMed ID: 20101098
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
20. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of
Happel C; Kranert WT; Gröner D; Baumgarten J; Halstenberg J; Bockisch B; Sabet A; Grünwald F
Endocrine; 2021 Jul; 73(1):125-130. PubMed ID: 33439464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
